Last reviewed · How we verify
BDD with UDCA
BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis.
BDD (a bile acid derivative) combined with UDCA (ursodeoxycholic acid) enhances bile acid signaling and reduces hepatic inflammation and cholestasis. Used for Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC) or other cholestatic liver disease.
At a glance
| Generic name | BDD with UDCA |
|---|---|
| Also known as | UDEX |
| Sponsor | Ewha Womans University Mokdong Hospital |
| Drug class | Bile acid derivative combination |
| Target | FXR (farnesoid X receptor) / TGR5 (likely) |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
UDCA is a hydrophilic bile acid that reduces the hydrophobicity of the bile acid pool and protects hepatocytes from cytotoxic bile acids. BDD likely acts as a farnesoid X receptor (FXR) agonist or bile acid receptor modulator to enhance cytoprotective signaling. Together, they reduce cholestasis, hepatic inflammation, and fibrosis progression in cholestatic liver diseases.
Approved indications
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC) or other cholestatic liver disease
Common side effects
- Pruritus
- Gastrointestinal disturbance
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDD with UDCA CI brief — competitive landscape report
- BDD with UDCA updates RSS · CI watch RSS
- Ewha Womans University Mokdong Hospital portfolio CI